A developing country response to Lavery <it>et al</it>. "In global health research, is it legitimate to stop clinical trials early on account of their opportunity costs?"
<p>Abstract</p> <p>Background</p> <p>A recent paper presents an argument and mechanism for the possible stopping of clinical trials early based on opportunity costs.</p> <p>Discussion</p> <p>Although we agree that the costs and opportunity costs...
Main Authors: | , |
---|---|
Format: | Article |
Language: | English |
Published: |
BMC
2009-09-01
|
Series: | BMC Medical Ethics |
Online Access: | http://www.biomedcentral.com/1472-6939/10/16 |
id |
doaj-58c34c7a232547a3869390bd84c595cf |
---|---|
record_format |
Article |
spelling |
doaj-58c34c7a232547a3869390bd84c595cf2020-11-25T03:45:09ZengBMCBMC Medical Ethics1472-69392009-09-011011610.1186/1472-6939-10-16A developing country response to Lavery <it>et al</it>. "In global health research, is it legitimate to stop clinical trials early on account of their opportunity costs?"Wassenaar Douglas RRamjee Gita<p>Abstract</p> <p>Background</p> <p>A recent paper presents an argument and mechanism for the possible stopping of clinical trials early based on opportunity costs.</p> <p>Discussion</p> <p>Although we agree that the costs and opportunity costs of clinical trials need to be reduced wherever possible, we raise concerns about the motivation and mechanism for stopping clinical trials early raised by Lavery <it>et al</it>.</p> <p>Summary</p> <p>We argue that there are already enough acceptable criteria and actors in the clinical trials arena to justify early stoppage of clinical trials, and argue that factors other than efficacy need to be carefully considered, especially in developing country contexts.</p> http://www.biomedcentral.com/1472-6939/10/16 |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Wassenaar Douglas R Ramjee Gita |
spellingShingle |
Wassenaar Douglas R Ramjee Gita A developing country response to Lavery <it>et al</it>. "In global health research, is it legitimate to stop clinical trials early on account of their opportunity costs?" BMC Medical Ethics |
author_facet |
Wassenaar Douglas R Ramjee Gita |
author_sort |
Wassenaar Douglas R |
title |
A developing country response to Lavery <it>et al</it>. "In global health research, is it legitimate to stop clinical trials early on account of their opportunity costs?" |
title_short |
A developing country response to Lavery <it>et al</it>. "In global health research, is it legitimate to stop clinical trials early on account of their opportunity costs?" |
title_full |
A developing country response to Lavery <it>et al</it>. "In global health research, is it legitimate to stop clinical trials early on account of their opportunity costs?" |
title_fullStr |
A developing country response to Lavery <it>et al</it>. "In global health research, is it legitimate to stop clinical trials early on account of their opportunity costs?" |
title_full_unstemmed |
A developing country response to Lavery <it>et al</it>. "In global health research, is it legitimate to stop clinical trials early on account of their opportunity costs?" |
title_sort |
developing country response to lavery <it>et al</it>. "in global health research, is it legitimate to stop clinical trials early on account of their opportunity costs?" |
publisher |
BMC |
series |
BMC Medical Ethics |
issn |
1472-6939 |
publishDate |
2009-09-01 |
description |
<p>Abstract</p> <p>Background</p> <p>A recent paper presents an argument and mechanism for the possible stopping of clinical trials early based on opportunity costs.</p> <p>Discussion</p> <p>Although we agree that the costs and opportunity costs of clinical trials need to be reduced wherever possible, we raise concerns about the motivation and mechanism for stopping clinical trials early raised by Lavery <it>et al</it>.</p> <p>Summary</p> <p>We argue that there are already enough acceptable criteria and actors in the clinical trials arena to justify early stoppage of clinical trials, and argue that factors other than efficacy need to be carefully considered, especially in developing country contexts.</p> |
url |
http://www.biomedcentral.com/1472-6939/10/16 |
work_keys_str_mv |
AT wassenaardouglasr adevelopingcountryresponsetolaveryitetalitinglobalhealthresearchisitlegitimatetostopclinicaltrialsearlyonaccountoftheiropportunitycosts AT ramjeegita adevelopingcountryresponsetolaveryitetalitinglobalhealthresearchisitlegitimatetostopclinicaltrialsearlyonaccountoftheiropportunitycosts AT wassenaardouglasr developingcountryresponsetolaveryitetalitinglobalhealthresearchisitlegitimatetostopclinicaltrialsearlyonaccountoftheiropportunitycosts AT ramjeegita developingcountryresponsetolaveryitetalitinglobalhealthresearchisitlegitimatetostopclinicaltrialsearlyonaccountoftheiropportunitycosts |
_version_ |
1724510872903090176 |